SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

2/14/22 5:03:05 PM ET

Ophthalmic Goods

Health Care

Get the next $STAA alert in real time by email

SC 13G/A 1 staar.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 11)* STAAR Surgical Co (Name of Issuer) Common Stock (Title of Class of Securities) 852312305 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ X ] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 852312305 13G Page 2 of 10 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Patrick Lee, MD 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,140,511 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,140,511 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,140,511 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.40% 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 852312305 13G Page 3 of 10 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Anthony Joonkyoo Yun, MD 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,140,511 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,140,511 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,140,511 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.40% 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. 852312305 13G Page 4 of 10 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Palo Alto Investors LP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,140,511 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,140,511 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,140,511 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.40% 12. TYPE OF REPORTING PERSON (see instructions) OO, IA CUSIP No. 852312305 13G Page 5 of 10 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) PAI LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION California NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,140,511 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,140,511 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,140,511 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.40% 12. TYPE OF REPORTING PERSON (see instructions) OO, IA CUSIP No. 852312305 13G Page 6 of 10 Pages Item 1. (a) Name of Issuer STAAR Surgical Company (b) Address of Issuer's Principal Executive Offices 25651 Atlantic Ocean Drive, Lake Forest, CA, 94630 Item 2. (a) Name of Person Filing Palo Alto Investors LP ("PAI"), PAI LLC ("PAI GP"),Patrick Lee, MD Anthony Joonkyoo Yun, MD (collectively, the "Filers"). (b) The address of the principal place of the Filers is located at: 470 University Avenue, Palo Alto, CA 94301 (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common Stock (e) CUSIP Number 852312305 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (as to PAI) (f) [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); CUSIP No. 852312305 13G Page 7 of 10 Pages (g) [x] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (as to Dr. Lee and Dr. Yun). (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J). CUSIP No. 852312305 13G Page 8 of 10 Pages Item 4. Ownership. See Items 5-9 and 11 of the cover page for each Filer. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A Item 8. Identification and Classification of Members of the Group. Dr. Lee and Dr. Yun co-manage PAI. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each of them expressly disclaims membership in a group. Each Filer disclaims beneficial ownership of the Stock except to the extent of that Filer's pecuniary interest therein. Item 9. Notice of Dissolution of Group. N/A CUSIP No. 852312305 13G Page 9 of 10 Pages Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits, Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct., Dated: February 14, 2022 PALO ALTO INVESTORS LP By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer, PAI LLC, By: /s/ Patrick Lee, MD, /s/ Patrick Lee, MD, /s/ Anthony Joonkyoo Yun, MD CUSIP No. 852312305 13G Page 10 of 10 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G, The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales by the undersigned of the securities of any issuer until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. For that purpose, the undersigned hereby constitute and appoint Palo Alto Investors, LP, a California limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases and sales, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present, until such time as the undersigned file with the SEC a statement terminating this Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. Dated: February 14, 2022, PALO ALTO INVESTORS LP By: /s/ Angela Nguyen-Dinh, Chief Compliance Officer, PAI LLC. By: /s/ Patrick Lee, MD, /s/ Patrick Lee, MD, /s/ Anthony Joonkyoo Yun, MD

Get the next $STAA alert in real time by email

Recent Analyst Ratings for

$STAA

Date	Price Target	Rating	Analyst
2/3/2026	$26.00	Neutral	Wedbush
1/16/2026	$13.00	Underweight	Morgan Stanley
4/21/2025	$17.00	Equal Weight	Wells Fargo
2/12/2025		Buy → Hold	Jefferies
2/12/2025	$45.00 → $17.00	Outperform → Neutral	Mizuho
2/12/2025		Buy → Neutral	BTIG Research
2/12/2025		Outperform → Mkt Perform	William Blair
7/15/2024	$50.00 → $37.00	Equal-Weight → Underweight	Morgan Stanley

More analyst ratings

SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

2/14/22 5:03:05 PM ET

$STAA

Ophthalmic Goods

Health Care

Get the next $STAA alert in real time by email

Recent Analyst Ratings for

$STAA

Date	Price Target	Rating	Analyst
2/3/2026	$26.00	Neutral	Wedbush
1/16/2026	$13.00	Underweight	Morgan Stanley
4/21/2025	$17.00	Equal Weight	Wells Fargo
2/12/2025		Buy → Hold	Jefferies
2/12/2025	$45.00 → $17.00	Outperform → Neutral	Mizuho
2/12/2025		Buy → Neutral	BTIG Research
2/12/2025		Outperform → Mkt Perform	William Blair
7/15/2024	$50.00 → $37.00	Equal-Weight → Underweight	Morgan Stanley

More analyst ratings

SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$STAA

SEC Form SC 13G/A filed by STAAR Surgical Company (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$STAA

$STAA
Insider Purchases

Director Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $606,138 worth of shares (27,485 units at $22.05) (SEC Form 4)

Large owner Broadwood Partners, L.P. bought $8,817,664 worth of shares (406,653 units at $21.68) (SEC Form 4)

$STAA
Analyst Ratings

Wedbush initiated coverage on STAAR Surgical with a new price target

Morgan Stanley resumed coverage on STAAR Surgical with a new price target

Wells Fargo initiated coverage on STAAR Surgical with a new price target

$STAA
Insider Trading

Interim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)

SEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J

Chief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)

$STAA
SEC Filings

STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by STAAR Surgical Company

STAAR Surgical Company filed SEC Form 8-K: Leadership Update

$STAA
Press Releases

STAAR Surgical Issues Shareholder Letter

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

$STAA
Leadership Updates

STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process

$STAA
Financials

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

STAAR Surgical Reports Third Quarter 2025 Results

$STAA
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by STAAR Surgical Company